Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-07-01 21:00 |
Biophytis announces the issuance of a €3 million tranche of ORNANE
|
English | 222.7 KB | ||
| 2020-06-23 08:00 |
Biophytis successfully completes a € 4 million capital increase to strengthen i…
|
English | 166.6 KB | ||
| 2020-06-23 08:00 |
Biophytis réalise avec succès une augmentation de capital de 4 millions d’euro…
|
French | 169.7 KB | ||
| 2020-03-03 08:00 |
Biophytis to Present the Preliminary Results of SARA-OBS and its Impact on SARA…
|
English | 179.8 KB | ||
| 2020-03-03 08:00 |
Biophytis présente les résultats préliminaires de SARA-OBS et l’impact sur SARA…
|
French | 147.7 KB | ||
| 2020-02-14 08:01 |
Biophytis Trading will resume on February 14th, 2020 at 09:00 CET
|
English | 159.0 KB | ||
| 2020-02-14 08:01 |
Reprise de la cotation de Biophytis le 14 février 2020 à 9h00
|
French | 126.2 KB | ||
| 2020-02-14 08:00 |
Biophytis successfully completes a € 3.3 million capital increase to strengthen…
|
English | 224.2 KB | ||
| 2020-02-14 08:00 |
Biophytis réalise avec succès une augmentation de capital de 3,3 M€ pour renfor…
|
French | 226.6 KB | ||
| 2020-02-13 08:00 |
Biophytis shares trading is suspended pending a new press release
|
English | 151.4 KB | ||
| 2020-02-13 08:00 |
Suspension de cours dans l'attente d'un nouveau communiqué
|
French | 126.0 KB | ||
| 2020-02-11 08:00 |
Biophytis - Protocol Amendment of SARA-INT, a Phase 2b Clinical Trial of Sarcon…
|
English | 293.6 KB | ||
| 2020-02-11 08:00 |
Biophytis – Approbation par la FDA et l’AFMPS de l’amendement apporté au protoc…
|
French | 244.0 KB | ||
| 2020-01-27 08:00 |
Biophytis SARA-INT Phase 2b study, evaluating the efficacy of Sarconeos (BIO101…
|
English | 159.8 KB | ||
| 2020-01-27 08:00 |
Biophytis annonce avoir recruté plus de 50% des patients dans l’étude de Phase …
|
French | 231.0 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
